Advertisement

Immunologische Aspekte in der Reproduktionsmedizin

  • Michael K. Bohlmann
Living reference work entry
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Untersuchungen immunologischer Aspekte der embryo-maternalen Interaktionen nehmen in der Reproduktionsmedizin eine immer größere Rolle ein. Störungen von Adhäsion, Invasion und Implantation der semi-allogenen Blastozyste in das rezeptive Endometrium werden als Ursache für Fehlgeburten oder andere – spätere – Schwangerschaftskomplikationen angesehen. Bis dato sind diese hochspezifischen, synchronen Abläufe an der embryo-maternalen Grenzfläche nur unzureichend verstanden. Die Gabe von aus anderen Indikationen als wirksam bekannten Medikamenten muss sich immer vor dem Hintergrund einer korrekten „immunologischen Diagnose“, zutreffender Indikation und dem potenziellen Nebenwirkungsspektrum der Präparate messen lassen. Da aufgrund der Studienlage evidenzbasierte Vorgehensweisen in aller Regel nicht gegeben sind, ist vom routinemäßigen Einsatz immunmodulatorischer Präparate außerhalb von Studien bis dato abzuraten.

Literatur

  1. Agrawal S, Pandey MK, Mandal S, Mishra L, Agarwal S (2002) Humoral immune response to an allogenic foetus in normal fertile women and recurrent aborters. BMC Pregnancy Childbirth 2:6CrossRefPubMedPubMedCentralGoogle Scholar
  2. Alecsandru D, García-Velasco JA (2017) Why natural killer cells are not enough: a further understanding of killer immunoglobulin-like receptor and human leukocyte antigen. Fertil Steril 107:1273–1278CrossRefPubMedGoogle Scholar
  3. Bohlmann MK (2011) Effects and effectiveness of heparin in assisted reproduction. J Reprod Immunol 90:82–90CrossRefPubMedGoogle Scholar
  4. Bohlmann MK, Lüdders DW, Baumann K, Speer R, Marx TE, Diedrich K, Hornemann A (2008) Gestagenanwendung in der Schwangerschaft. Gynäkol Endokrinol 6:171–176CrossRefGoogle Scholar
  5. Bohlmann MK, Luedders DW, Weichert J, Baumann K, Thill M, Diedrich K, Schleussner E, Hornemann A (2009) Thrombophile Gerinnungsstörungen als Risikofaktoren für habituelle Aborte. Gynäkologe 42:17–24CrossRefGoogle Scholar
  6. Bohlmann MK, Toth B, Schleussner E (2010) Keine generelle Heparinisierung bei habituellen Aborten. Frauenarzt 51:1020–1021Google Scholar
  7. Carp HJ, Toder V, Mashiach S, Rabinovici J (1994) Effect of paternal leukocyte immunization on implantation after biochemical pregnancies and repeated failure of embryo transfer. Am J Reprod Immunol 31:112–115CrossRefPubMedGoogle Scholar
  8. Carrington B, Sacks G, Regan L (2005) Recurrent miscarriage: pathophysiology and outcome. Curr Opin Obstet Gynecol 17:591–597CrossRefPubMedGoogle Scholar
  9. Carter JD, Valeriano J, Vasey FB (2006) Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 33:1014–1017PubMedGoogle Scholar
  10. Clark DA (2010) Anti-TNF alpha therapy in immune-mediated subfertility: state of the art. J Reprod Immunol 85:15–24CrossRefPubMedGoogle Scholar
  11. Clowse ME (2010) The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Womens Health 2:199–209CrossRefPubMedPubMedCentralGoogle Scholar
  12. Davari-Tanha F, Shahrokh Tehraninejad E, Ghazi M, Shahraki Z (2016) The role of G-CSF in recurrent implantation failure: a randomized double blind placebo control trial. Int J Reprod Biomed (Yazd) 14:737–742CrossRefGoogle Scholar
  13. Daya S, Gunby J (2004) Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev (3):CD004830Google Scholar
  14. Fahey JV, Schaefer TM, Channon JY, Wira CR (2005) Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum Reprod 20:1439–1446CrossRefPubMedGoogle Scholar
  15. Franasiak JM, Scott RT (2017) Contribution of immunology to implantation failure of euploid embryos. Fertil Steril 107:1279–1283CrossRefPubMedGoogle Scholar
  16. Gleicher N, Vidali A, Barad DH (2011) Successful treatment of unresponsive thin endometrium. Fertil Steril 95(2123):e13–e17Google Scholar
  17. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM (2006) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 66:8026–8036CrossRefPubMedGoogle Scholar
  18. Haas DM, Ramsey PS (2013) Progestogen for preventing miscarriage. Cochrane Database Syst Rev (10):CD003511Google Scholar
  19. Haider S, Knöfler M (2009) Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta 30:111–123CrossRefPubMedGoogle Scholar
  20. Hofer S, Heindl B, Meister FC, Maul H, Martin E, Sohn C, Weigand MA (2009) Blutungen während Schwangerschaft und Geburt. Gynäkologe 42:55–69CrossRefGoogle Scholar
  21. Ito K, Tanaka T, Tsutsumi N, Obata F, Kashiwagi N (1999) Possible mechanisms of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: analysis of anti-idiotypic antibodies directed against autologous T-cell receptors. Hum Reprod 14:650–655CrossRefPubMedGoogle Scholar
  22. Kallen CB, Arici A (2003) Immune testing in fertility practice: truth or deception? Curr Opin Obstet Gynecol 18:440–445Google Scholar
  23. Kämmerer U, von Wolff M, Markert UR (2004) Immunology of human endometrium. Immunobiology 209:569–574CrossRefPubMedGoogle Scholar
  24. Kleinstein J (2009) Aktive und passive Immunisierung. Gyn Endokrinol 7:87–92CrossRefGoogle Scholar
  25. Kling C, Steinmann J, Westphal E, Magez J, Kabelitz D (2006) Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum Reprod 21:429–435CrossRefPubMedGoogle Scholar
  26. Kling C, Schmutzler A, Wilke G, Hedderich J, Kabelitz D (2008) Two-year outcome after recurrent implantation failure: prognostic factors and additional interventions. Arch Gynecol Obstet 278:135–142CrossRefPubMedPubMedCentralGoogle Scholar
  27. Lédée N, Petitbarat M, Rahmati M, Dubanchet S, Chaouat G, Sandra O, Perrier-d’Hauterive S, Munaut C, Foidart JM (2011) New pre-conception immune biomarkers for clinical practice: interleukin-18, interleukin-15 and TWEAK on the endometrial side, G-CSF on the follicular side. J Reprod Immunol 88:118–123Google Scholar
  28. Li J, Chen Y, Liu C, Hu Y, Li L (2013) Intravenous immunoglobulin treatment for repeated IVF/ICSI failure and unexplained infertility: a systematic review and a meta-analysis. Am J Reprod Immunol 70:434–447CrossRefPubMedGoogle Scholar
  29. Matsuyama T, Kobayashi Y, Honda I, Inoue M, Fujii A (1992) Analysis of HLA antigens and immunotherapy for infertile couples who failed to conceive after in vitro fertilization-embryo tubal replacement (IVF-ETR). Nihon Sanka Fujinka Gakkai Zasshi 44:1241–1247PubMedGoogle Scholar
  30. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefGoogle Scholar
  31. Moffett A, Shreeve N (2015) First do no harm: uterine natural killer (NK) cells in assisted reproduction. Hum Reprod 30:1519–1525CrossRefPubMedPubMedCentralGoogle Scholar
  32. Nelson SM, Greer IA (2008) The potential role of heparin in assisted conception. Hum Reprod Update 14:623–645CrossRefPubMedGoogle Scholar
  33. Oates-Whitehead RM, Haas DM, Carrier JA (2003) Progestogen for preventing miscarriage. Cochrane Database Syst Rev (4):CD003511Google Scholar
  34. Pandey MK, Rani R, Agrawal S (2005) An update in recurrent spontaneous abortion. Arch Gynecol Obstet 272:95–108CrossRefPubMedGoogle Scholar
  35. Parham P (2004) NK cells and trophoblasts: partners in pregnancy. J Exp Med 200:951–955CrossRefPubMedPubMedCentralGoogle Scholar
  36. Paulmyer-Lacroix O, Despierres L, Courbiere B, Bardin N (2014) Antiphospholipid antibodies in women undergoing in vitro fertilization treatment: clinical value of IgA anti-β2glycoprotein I antibodies determination. Biomed Res Int 2014, Art.314704Google Scholar
  37. Piccinni MP, Giudizi MG, Biagiotti R, Beloni L, Giannarini L, Zampognaro S, Parrochi P, Manetti R, Annunziato F, Livi C, Romagnani S, Maggi E (1995) Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol 155:128–133PubMedGoogle Scholar
  38. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S (1998) Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 4:1020–1024CrossRefPubMedGoogle Scholar
  39. Practice Committee of the American Society for Reproductive Medicine (2008) Definitions of infertility and recurrent pregnancy loss. Fertil Steril 90:60Google Scholar
  40. Quack KC, Vassiliadou N, Pudney J, Anderson DJ, Hill JA (2001) Leukocyte activation in the decidua of chromosomally normal and abnormal fetuses from women with recurrent abortion. Hum Reprod 16:949–955CrossRefPubMedGoogle Scholar
  41. Quenby S, Bates M, Doig T, Brewster J, Lewis-Jones DI, Johnson PM, Vince G (1999) Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum Reprod 14:2386–2391CrossRefPubMedGoogle Scholar
  42. Rode L, Langhoff-Roos J, Andersson C, Dinesen J, Hammerum MS, Mohapeloa H, Tabor A (2009) Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies. Acta Obstet Gynecol Scand 88:1180–1189CrossRefPubMedGoogle Scholar
  43. Rogenhofer N, Mittenzwei S, Thaler CJ, Diedrich K, Baumann K, Bohlmann MK (2011) Stellenwert der aktiven Immuntherapie bei Kinderwunschpatientinnen. Gyn Endokrinol 9:215–218CrossRefGoogle Scholar
  44. Royal College of Obstetricians and Gynaecologist – RCOG. Guideline No. 17. The investigation and treatment of couples with recurrent miscarriage. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf. Zugegriffen am 06.07.2018
  45. Sacks G (2015) Enough! Stop the arguments and get on with the science of natural killer cell testing. Hum Reprod 30:1526–1531CrossRefPubMedGoogle Scholar
  46. Salmassi A, Schmutzler AG, Schaefer S, Koch K, Hedderich J, Jonat W, Mettler L (2005) Is granulocyte colony-stimulating factor level predictive for human IVF outcome? Hum Reprod 20:2434–2440CrossRefPubMedGoogle Scholar
  47. Scarpellini F, Sbracia M (2009) Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. Hum Reprod 24:2703–2708CrossRefPubMedGoogle Scholar
  48. Schindler AE (2005) Einsatz von Gestagenen in der Schwangerschaft – Therapeutische und präventive Anwendungsmöglichkeiten. Frauenarzt 46:586–589Google Scholar
  49. Shakhar K, Rosenne E, Loewenthal R, Shakhar G, Carp H, Ben-Eliyahu S (2006) High NK cell activity in recurrent miscarriage: what are we really measuring? Hum Reprod 21:2421–2425CrossRefPubMedGoogle Scholar
  50. Steinvil A, Raz R, Berliner S, Steinberg DM, Zeltser D, Levran D, Shimron O, Sella T, Chodick G, Shalev V, Salomon O (2012) Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation. Thromb Haemost 108:1192–1197CrossRefPubMedGoogle Scholar
  51. Strowitzki T, Germeyer A, Popovici R, von Wolff M (2006) The human endometrium as a fertility-determining factor. Hum Reprod Update 12:617–630CrossRefPubMedGoogle Scholar
  52. Sung N, Han AR, Park CW, Park DW, Park JC, Kim NY, Lim KS, Shin JE, Joo CW, Lee SE, Kim JW, Lee SK, Task Force IVIG (2017) Korean society for reproductive immunology. Intravenous immunoglobulin G in women with reproductive failure: The Korean society for reproductive immunology practice guidelines. Clin Exp Reprod Med 44:1–7CrossRefPubMedPubMedCentralGoogle Scholar
  53. Tanaka T, Miyama M, Masuda M, Mizuno K, Sakamoto T, Umesaki N, Ogita S (2000) Production and physiological function of granulocyte colony-stimulating factor in non-pregnant human endometrial stromal cells. Gynecol Endocrinol 14:399–404CrossRefPubMedGoogle Scholar
  54. Toth B, Tempfer C, Bohlmann MK, Hancke K, Nawroth F, Schleußner E, Rogenhofer N, Rudnik-Schöneborn S, von Otte S, von Wolff M, Wischmann T, Würfel W, Zschocke J (2018) Diagnostik und Therapie beim wiederholten Spontanabort; AWMF-Leitlinie 015/050 (S2k). Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) (im Druck)Google Scholar
  55. Wilczyński JR, Radwan P, Tchórzewski H, Banasik M (2012) Immunotherapy of patients with recurrent spontaneous miscarriage and idiopathic infertility: does the immunization-dependent Th2 cytokine overbalance really matter? Arch Immunol Ther Exp (Warsz) 60:151–160CrossRefGoogle Scholar
  56. Winger EE, Reed JL (2009) Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 60:8–16CrossRefGoogle Scholar
  57. Winger EE, Reed JL, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M (2009) Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 61:113–120CrossRefPubMedGoogle Scholar
  58. Winger EE, Reed JL, Ashoush S, El-Toukhy T, Ahuja S, Taranissi M (2011a) Degree of TNF-α/IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with Adalimumab (Humira) and IVIG. Am J Reprod Immunol 65:610–618CrossRefPubMedGoogle Scholar
  59. Winger EE, Reed JL, Ashoush S, El-Toukhy T, Ahuja S, Taranissi M (2011b) Birth defect rates in women using adalimumab (Humira) and intravenous immunoglobulin to treat immunologic-based infertility in IVF. Am J Reprod Immunol 66:237–241CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.FrauenklinikUniverstätsmedizin MannheimMannheimDeutschland

Personalised recommendations